S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
3 Words and a 3,000% Return (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
3 Words and a 3,000% Return (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Ukraine targets a key Crimean city a day after striking Russia's Black Sea Fleet headquarters
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
3 Words and a 3,000% Return (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
3 Words and a 3,000% Return (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Ukraine targets a key Crimean city a day after striking Russia's Black Sea Fleet headquarters
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
3 Words and a 3,000% Return (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
3 Words and a 3,000% Return (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Ukraine targets a key Crimean city a day after striking Russia's Black Sea Fleet headquarters
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
3 Words and a 3,000% Return (Ad)
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
3 Words and a 3,000% Return (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Ukraine targets a key Crimean city a day after striking Russia's Black Sea Fleet headquarters
NASDAQ:GMAB

Genmab A/S (GMAB) Stock Forecast, Price & News

$36.08
-0.41 (-1.12%)
(As of 09/22/2023 ET)
Compare
Today's Range
$35.98
$36.42
50-Day Range
$36.07
$42.25
52-Week Range
$31.40
$47.50
Volume
315,497 shs
Average Volume
382,735 shs
Market Capitalization
$23.83 billion
P/E Ratio
36.08
Dividend Yield
N/A
Price Target
$41.40

Genmab A/S MarketRank™ Forecast

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
14.7% Upside
$41.40 Price Target
Short Interest
Healthy
0.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
17.65%
From $1.02 to $1.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

137th out of 969 stocks

Pharmaceutical Preparations Industry

42nd out of 440 stocks


GMAB stock logo

About Genmab A/S (NASDAQ:GMAB) Stock

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GMAB Price History

GMAB Stock News Headlines

H.C. Wainwright Keeps Their Buy Rating on Genmab (GMAB)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Why Shares of Zai Lab Limited Were Jumping on Tuesday
Genmab Is Down To Attractive Levels
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Analyst Expectations for Genmab's Future
Genmab (GMAB) Receives a Buy from Truist Financial
Genmab A/S: Genmab Updates 2023 Financial Guidance
12 Analysts Have This to Say About Genmab
Morgan Stanley Keeps Their Sell Rating on Genmab (GMAB)
See More Headlines
Receive GMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GMAB Company Calendar

Last Earnings
8/03/2023
Today
9/23/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMAB
Fax
N/A
Employees
1,660
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$41.40
High Stock Price Forecast
$54.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+14.7%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
15 Analysts

Profitability

Net Income
$781.91 million
Pretax Margin
36.62%

Debt

Sales & Book Value

Annual Sales
$2.07 billion
Cash Flow
$1.25 per share
Book Value
$5.89 per share

Miscellaneous

Free Float
650,398,000
Market Cap
$23.83 billion
Optionable
Not Optionable
Beta
0.94

Social Links

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 62)
    Co-Founder, Pres & CEO
    Comp: $2.71M
  • Mr. Anthony Pagano (Age 45)
    Exec. VP & CFO
    Comp: $1.01M
  • Mr. Anthony Mancini (Age 52)
    Exec. VP & COO
    Comp: $1.1M
  • Mr. Martin Schultz (Age 47)
    Sr. Director of Clinical Operations & Non-Independent Director
    Comp: $72.04k
  • Dr. Judith V. Klimovsky M.D. (Age 65)
    Exec. VP & Chief Devel. Officer
    Comp: $1.14M
  • Dr. Tahamtan Ahmadi (Age 50)
    Exec. VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $1.08M
  • Dr. Mijke Zachariasse Ph.D. (Age 49)
    Sr. Director, Head of Antibody Research Materials & Non-Independent Director
    Comp: $144.08k
  • Mr. Takahiro Hamatani (Age 48)
    Sr. Director of Fin. Japan & Non-Independent Director
    Comp: $72.04k
  • Mr. Andrew Carlsen
    Sr. Director, VP & Head of Investor Relations
  • Ms. Birgitte Stephensen M.Sc. (Age 62)
    Exec. VP & Chief Legal Officer













GMAB Stock - Frequently Asked Questions

Should I buy or sell Genmab A/S stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GMAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View GMAB analyst ratings
or view top-rated stocks.

What is Genmab A/S's stock price forecast for 2023?

15 equities research analysts have issued 1-year price targets for Genmab A/S's stock. Their GMAB share price forecasts range from $23.00 to $54.00. On average, they predict the company's stock price to reach $41.40 in the next year. This suggests a possible upside of 14.7% from the stock's current price.
View analysts price targets for GMAB
or view top-rated stocks among Wall Street analysts.

How have GMAB shares performed in 2023?

Genmab A/S's stock was trading at $42.38 at the beginning of the year. Since then, GMAB stock has decreased by 14.9% and is now trading at $36.08.
View the best growth stocks for 2023 here
.

Are investors shorting Genmab A/S?

Genmab A/S saw a drop in short interest in August. As of August 31st, there was short interest totaling 2,890,000 shares, a drop of 16.2% from the August 15th total of 3,450,000 shares. Based on an average daily volume of 485,500 shares, the days-to-cover ratio is presently 6.0 days.
View Genmab A/S's Short Interest
.

When is Genmab A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our GMAB earnings forecast
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) issued its quarterly earnings results on Thursday, August, 3rd. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $0.01. The business earned $613.43 million during the quarter, compared to the consensus estimate of $618.77 million. Genmab A/S had a trailing twelve-month return on equity of 16.93% and a net margin of 28.78%.

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S issued an update on its FY 2023 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.27 billion-$2.41 billion, compared to the consensus revenue estimate of $2.38 billion.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

(GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies served as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.24%), BlackRock Inc. (0.79%), Capital International Investors (0.64%), Renaissance Technologies LLC (0.13%), Stifel Financial Corp (0.11%) and Royal Bank of Canada (0.11%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $36.08.

How much money does Genmab A/S make?

Genmab A/S (NASDAQ:GMAB) has a market capitalization of $23.83 billion and generates $2.07 billion in revenue each year. The company earns $781.91 million in net income (profit) each year or $1.00 on an earnings per share basis.

How many employees does Genmab A/S have?

The company employs 1,660 workers across the globe.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728 or via email at acn@genmab.com.

This page (NASDAQ:GMAB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -